Core Insights - Alcon, Inc. reported a fourth-quarter 2024 core EPS of 72 cents, reflecting a 2.9% increase year-over-year and exceeding the Zacks Consensus Estimate by 2.9% [1][2] - The full-year core EPS for 2024 was $3.05, up 11.3% year-over-year, also surpassing the Zacks Consensus Estimate by 0.7% [2] Revenue Performance - Alcon's net sales for the fourth quarter reached $2.48 billion, exceeding the Zacks Consensus Estimate by 0.7% and marking a 6.2% increase from the previous year [4] - For the full year 2024, net sales totaled $9.84 billion, up 5% year-over-year, again surpassing the Zacks Consensus Estimate by 0.2% [4] Segment Analysis - Surgical segment sales were $1.40 billion, up 5% year-over-year, with Implantables sales increasing by 2% at constant exchange rates (CER) [6] - Consumables net sales grew by 7% at CER, driven by vitreoretinal and cataract consumables [7] - Vision Care segment reported total sales of $1.10 billion, an 8% increase year-over-year, with Contact Lenses sales rising 11% at CER [8] Margin and Cost Analysis - The cost of net sales in Q4 was $1.09 billion, a 4.2% increase year-over-year, while core gross profit rose by 7.9% to $1.38 billion [11] - Core gross margin expanded by 86 basis points to 55.9%, and core operating margin increased by 208 basis points to 14.1% [11] Financial Position - Alcon ended 2024 with cash and cash equivalents of $1.68 billion, up from $1.09 billion at the end of 2023 [12] - Cumulative net cash flow from operating activities was $2.08 billion, compared to $1.39 billion in the previous year, with free cash flow totaling $1.60 billion [12] 2025 Outlook - Alcon anticipates 2025 net sales between $10.2 billion and $10.4 billion, indicating a year-over-year growth of 6-8% at CER [13] - Core EPS for 2025 is expected to be in the range of $3.15 to $3.25, suggesting growth of 8-11% at CER from 2024 levels [13] Overall Performance - Alcon's fourth-quarter results exceeded expectations, driven by strong demand for innovative products and effective execution [14] - The growth in the Vision Care segment highlights the strength of contact lenses, and margin expansion is viewed positively [14]